Our pipeline

Research programs
in cancer supportive care

TL-01 leads our portfolio of eight research programs in cancer supportive care.

Research & development portfolio

The portfolio includes serotonergic and non-serotonergic approaches at different stages of discovery and lead optimization.

Telesti research programs and current stages
ProgramResearch focusStage reached
TL-01Lead programLead neuroplastogen

We are developing TL-01 for cancer-related cognitive impairment, with the goal of an oral medicine suitable for oncology care.

Lead optimizationPreclinical research
TL-02Dual-action prodrug research

Chimeric compounds are being studied as dual-action prodrugs.

Hits synthesizedDiscovery
TL-03Neuroinflammation research

The research examines inflammatory biology and its relevance to cognitive function.

Hits synthesizedDiscovery
TL-04Short-acting CNS program

We are investigating compounds designed for a shorter duration of action.

Hit identificationEarly discovery
TL-05Neuroplastogen discovery

We are exploring novel neuroplastogen chemistry for cancer supportive care.

Hit identificationEarly discovery
TL-06Cognition-focused research

The research examines serotonergic approaches to cognitive function.

Hit identificationEarly discovery
TL-07HDAC6-targeted research

This program investigates a non-serotonergic approach to cognition and neuropathy.

Hit identificationEarly discovery
TL-08TrkB-targeted research

This program explores neurotrophic signaling through a non-serotonergic approach.

DiscoveryPre-candidate research

Each marker identifies the current research stage. The markers do not quantify completion or forecast future progress. All programs remain in discovery or preclinical research and none is in clinical development.

The descriptions summarize the aims of each research program. Therapeutic effects, safety and effectiveness have not been established.

Development priorities

Evaluating each program

Our development plans cover chemistry, pharmacology, safety, neural plasticity and disease-relevant outcomes.

TL-01 is our lead development priority. We are also exploring complementary biological approaches across the portfolio and will assess each program on its own evidence. Contact us for further information about our programs.

Contact our team